Jazz Pharmaceuticals/$JAZZ
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Jazz Pharmaceuticals
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Ticker
$JAZZ
Sector
Primary listing
Employees
2,800
Headquarters
Dublin, Ireland
Website
JAZZ Metrics
BasicAdvanced
$8.4B
-
-$6.63
0.28
-
Price and volume
Market cap
$8.4B
Beta
0.28
52-week high
$148.06
52-week low
$95.49
Average daily volume
639K
Financial strength
Current ratio
1.618
Quick ratio
1.151
Long term debt to equity
118.465
Total debt to equity
146.214
Interest coverage (TTM)
2.93%
Profitability
EBITDA (TTM)
1,419.54
Gross margin (TTM)
92.14%
Net profit margin (TTM)
-9.91%
Operating margin (TTM)
22.66%
Effective tax rate (TTM)
20.97%
Revenue per employee (TTM)
$1,460,000
Management effectiveness
Return on assets (TTM)
5.19%
Return on equity (TTM)
-10.84%
Valuation
Price to revenue (TTM)
2.058
Price to book
2.25
Price to tangible book (TTM)
-2.88
Price to free cash flow (TTM)
6.783
Free cash flow yield (TTM)
14.74%
Free cash flow per share (TTM)
20.32
Growth
Revenue change (TTM)
4.52%
Earnings per share change (TTM)
-211.89%
3-year revenue growth (CAGR)
5.49%
10-year revenue growth (CAGR)
12.33%
3-year earnings per share growth (CAGR)
99.18%
10-year earnings per share growth (CAGR)
4.89%
What the Analysts think about JAZZ
Analyst ratings (Buy, Hold, Sell) for Jazz Pharmaceuticals stock.
Bulls say / Bears say
Jazz faces a $145 million settlement to resolve Xyrem antitrust claims, which may impact cash flow and could encounter delays if judicial approval is postponed. (Reuters)
Modeyso showed tumor shrinkage in just 22% of diffuse midline glioma patients, and with only an estimated 3,940 affected individuals in the U.S., the drug's commercial potential is limited. (Reuters)
Zepzelca’s list price stays at $8,110 per dose for its first-line maintenance indication, which may cap additional revenue gains and could draw increased scrutiny from insurers. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2025.
JAZZ Financial Performance
Revenues and expenses
JAZZ Earnings Performance
Company profitability
JAZZ News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Jazz Pharmaceuticals stock?
Jazz Pharmaceuticals (JAZZ) has a market cap of $8.4B as of November 05, 2025.
What is the P/E ratio for Jazz Pharmaceuticals stock?
The price to earnings (P/E) ratio for Jazz Pharmaceuticals (JAZZ) stock is 0 as of November 05, 2025.
Does Jazz Pharmaceuticals stock pay dividends?
No, Jazz Pharmaceuticals (JAZZ) stock does not pay dividends to its shareholders as of November 05, 2025.
When is the next Jazz Pharmaceuticals dividend payment date?
Jazz Pharmaceuticals (JAZZ) stock does not pay dividends to its shareholders.
What is the beta indicator for Jazz Pharmaceuticals?
Jazz Pharmaceuticals (JAZZ) has a beta rating of 0.28. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.